• About
• Links
• Contact
• Sitemap

Sitemap > Clinical Trials > Oncology

• Bevacizumab and Abraxane as Second-Line Therapy in Triple Negative Metastatic Breast Cancer
• INNO-206 in Patients With Small Cell Lung Cancer
• Phase I Oral mTOR Inhibitor RAD001 in Combination With Capecitabine for Metastatic Breast Cancer
• Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib
• Study of Abiraterone Acetate in Patients With Prostate Cancer
• A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
• Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
• Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
• Phase I Study of Abiraterone Acetate in Hormone Refractory Prostate Cancer
• A Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
• A Phase II Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Failed Taxane-Based Chemotherapy
• Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension
• Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer.
• Bortezomib (Velcade) and Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma
• ABI-008 Trial in Patients With Hormone-Refractory Prostate Cancer
• A Phase II Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer
• Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
• Sorafenib With TACE to Treat Hepatocellular Carcinoma
• Sunitinib in Treating Patients With Recurrent or Metastatic Endometrial Cancer
• Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)
• A Study of Picoplatin in Colorectal Cancer
• Bortezomib in Combination With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
• Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer
• Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas in First Line of Treatment for the Metastatic Disease
• Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma
• Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)
• A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer
• Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
• Study of NGR-hTNF as Single Agent in Patients Affected by Metastatic Small Cell Lung Carcinoma
• Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Solid Tumors
• Oral CEP-701 With Chemotherapy to Patients With Acute Myeloid Leukemia (AML) Expressing FLT-3 Mutations
• A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
• Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
• Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Blood Stem Cell Transplant for Stage II or III Multiple Myeloma
• Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
• A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
• Erlotinib in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
• CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment
• Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
• Study of XL880 in Adults With Squamous Cell Cancer of the Head and Neck
• Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
• A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
• Phase II Anastrozole and ZD6474 in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
• Phase 2 Study of Panzem NCD in Combination With Fixed-Dose Temozolomide to Patients With Recurrent GBM
• A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
• Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
• A Phase 1/2a Study of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia
• Nilotinib as First-Line Treatment of Ph+ CML in Early Chronic Phase
• Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
• A Phase II, Single Arm, Prospective Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
• A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence
• A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
• Ofloxacin vs. Gentamicin as Prophylaxis Prior Transrectal Biopsy of Prostate
• A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer
• A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
• Gleevec & Docetaxel Study in Head and Neck Squamous Cell Cancer Patients
• A Phase II Study of EC17 (Folate-Hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
• Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors
• A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Females Aged 15-25 Years.
• Phase 2 Study Evaluating Clinical Efficacy, Safety, and Pharmacodynamic Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
• Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-Cyclophosphamide in Breast Cancer Patients
• Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors
• Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer
• Phase I, Open-Label, Dose-Escalation, Safety and PK Study of AZD4877 in Patients With AML
• Rituximab and Prednisone as First-Line Therapy in Treating Patients With Low Levels of Platelets in the Blood
• Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer
• Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma
• Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib
• Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Pazopanib With or Without Bicalutamide in Treating Patients With Hormone-Refractory Prostate Cancer
• Phase IIa Vorinostat Study in Lower Risk Myelodysplastic Syndromes
• A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma
• Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
• A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors
• Preliminary Study to Explore the Effects of Mirtazapine on Appetite in Advanced Cancer Patients
• Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension
• A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer
• Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC
• Trabectedin in Treating Patients With Unresectable, Advanced, or Metastatic Soft Tissue Sarcoma
• Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
• Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
• Phase I Study of Olanzapine for Cachexia
• Evaluation of Contrast-Enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases
• Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
• A Study Evaluating the Efficacy and Safety of Sutent With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer
• Atiprimod Treatment for Patients With Multiple Myeloma
• Bortezomib and Rituxan Study for Patients With Waldenstrom
• Aerosol L9-NC and Temozolomide in Ewing
• Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
• Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancers (LCCC 0403)
• Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients
• Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
• Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
• Daunorubicin, Arsenic Trioxide and Cytarabine With or Without Tretinoin, Mercaptopurine, and Methotrexate or Gemtuzumab in Treating Patients With Acute Promyelocytic Leukemia
• A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors
• Interleukin 11, Thrombocytopenia, CML, Imatinib in CML Patients
• Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer
• Study of Tumour Response to Tirapazamine During Treatment of Cervical Cancer
• AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer
• Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia
• Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes
• Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
• Open-Label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693
• Study of Nimotuzamab and Irintotecan in Metastatic Colorectal Cancer
• Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
• Study Evaluating the Efficacy & Pharmacokinetics of Temsirolimus (CCI-779) in Subjects With Advanced Renal Cell Carcinoma
• Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
• A Phase I/II Study of AZD2171 in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
• Phase III Study of BAY 43-9006 in Japanese Patients With Advanced Hepatocellular Carcinoma
• CEP-701 for PH-Negative MPD
• SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome
• Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
• A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
• A Phase I/II Study of Sunitinib and Dacarbazine
• Phase II Clinical Trial, Non-Randomized, Multicentre, on the Mixture of Gemcitabine, Capecitabine and Sorafenib (Bay 43-9006) in Treatment of Patients With Unresectable and/or Metastatic Renal Cell Carcinoma (RCC)
• MK2461 Phase I/II Study in Patients With Advanced Gastric Cancer and Other Solid Tumors
• Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-Line Therapy in HER2/Neu-Positive Breast Cancer
• ZK219477 in Patients With Breast Cancer and Brain Metastases
• phII Study of an HDAC Inhibitor in Very High-Risk Relapsed/Refractory Hodgkin
• A Study of TNFerade™ With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer
• Phase I Study of Patupilone and RAD001
• DAHANCA 19: The Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC
• ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer
• Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
• Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
• A Study of Apomab in Combination With Cetuximab and Irinotecan Chemotherapy in Patients With Previously Treated Metastatic Colorectal Cancer
• A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
• Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
• Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
• Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
• Sunitinib in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
• Phase I/II Trial of GS-9219 in Patients With NHL and CLL
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
• Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
• Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
• Sunitinib in Treating Patients With Recurrent Malignant Gliomas
• A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors
• Sirolimus in Treating Patients With Advanced Pancreatic Cancer
• Paclitaxel With or Without Sorafenib in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
• Erlotinib With or Without Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
• Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
• Letrozole and Lapatinib in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
• Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel
• Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
• Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
• Doxil, Gemcitabine and Velcade (PS341) in Advanced Cancer Patients
• Study of Addition of Panitumumab to Chemoradiation Therapy in Subjects With Locally Advanced Head and Neck Cancer
• An Open-Label, Dose Escalation Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors
• A Study of a Targeted Oral Agent for the Treatment of Renal Cell Carcinoma
• A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
• A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease
• Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery: an Intervention to Decrease Immune Suppression, Metastatic Potential and Cancer Recurrence
• Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers
• A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
• AZD2171 in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
• Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma
• A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
• Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia
• Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)
• Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
• SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
• Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Bevacizumab, and Gemcitabine as First-Line Therapy in Treating Patients With Metastatic Breast Cancer
• Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
• Azacitidine, Docetaxel, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
• Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer
• Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
• MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
• SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients
• Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
• Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer
• Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer
• A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
• Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies
• A Pilot Study of Imatinib in the Treatment of Refractory Systemic Sclerosis
• Randomized Phase 3b Study in Previously Untreated Multiple Myeloma Patients: VELCADE,Thalidomide, and Dexamethason Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone
• Phase 1/2 Study of VELCADE®, Dexamethasone, and Revlimid® Versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid in Patients With Previously Untreated Multiple Myeloma
• Dasatinib in Patients With Head and Neck Squamous Cell Carcinoma
• A Randomised, Double-Blind, Parallel Group, Multi-Centre, Phase II Study to Assess the Efficacy and Safety of Best Support Care (BSC) Plus ZD 6474 300 mg, BSC Plus ZD 6474 100 mg, and BSC Plus Placebo in Patients With Inoperable Hepatocellular Carcinoma (HCC)
• Bortezomib and High-Dose Melphalan at Myeloma Relapse
• Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
• Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
• Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer
• Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
• Fludarabine, Cyclophosphamide, and Vaccine Therapy in Treating Patients With Metastatic Melanoma
• Phase 1 Study With Sorafenib and Sirolimus
• Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
• Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
• Irinotecan (Camptosar) in Patients With Advanced Sarcomas
• Phase 3 Randomized Study of Amonafide and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary AML
• Efficacy and Safety of Everolimus (RAD001) in Female or Male Patients 18 Years or Older With Advanced Neuroendocrine Tumors
• A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer
• Sorafenib in Myelodysplastic Syndrome
• Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate
• Safety and Dose Study of GRN163L With Paclitaxel and Carboplatin to Treat Patients With Advanced or Metastatic Non Small Cell Lung Cancer
• Phase II Gleevec Study for Patients With Ovarian Cancer
• A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
• Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
• PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
• Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin
• Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
• Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
• Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
• A Phase I/II Study of AMD3100 With Mitoxantrone, Etoposide and Cytarabine (AMD3100+MEC) in Relapsed or Refractory AML
• Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE)
• A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer
• Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
• PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma
• Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer
• AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
• A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib
• Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
• Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide, Compared With Low-Dose Cytarabine Alone, for the Treatment of Elderly Patients With Acute Myeloid Leukemia
• AZD0530 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
• Sunitinib and Combination Chemotherapy Before Surgery in Treating Patients With Stage II or Stage III Breast Cancer
• Study of MDV3100 in Treating Patients With Progressive Prostate Cancer
• Phase 1 Study of OSI-930 in Cancer Patients
• Phase 1 Study of Continuous OSI-906 Dosing
• Vandetanib in Treating Young Patients With Medullary Thyroid Cancer
• Sunitinib in Treating Patients With Relapsed Multiple Myeloma
• Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
• A Multicenter, Open-Label Study of YM155 + Docetaxel + Prednisone in Men With Advanced Hormone Refractory Prostate Cancer
• Phase 1 Study of Intermittent OSI-906 Dosing
• Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
• A Study of Tanespimycin (KOS-953) in Patients With Relapsed-Refractory Multiple Myeloma
• Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia
• BIBW 2992 in Head & Neck Cancer
• Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
• Mistletoe as Complementary Treatment in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC), Treated With Carboplatin/Gemcitabine Chemotherapy Combination: Randomized Phase II Study
• RAD001 in Advanced Hepatocellular Carcinoma
• A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma
• VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
• A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
• Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors
• Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
• Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer
• Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
• Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
• Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors.
• Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer
• Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin
• Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin
• A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
• Dutasteride and Androgen-Ablation Therapy in Treating Patients With Localized Prostate Cancer Who Have Undergone Radiation Therapy and/or Surgery
• Sorafenib and Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
• Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
• A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease
• Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC
• Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
• Study of ABT-869 in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
• Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
• A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
• Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
• Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
• Dalteparin in Preventing Blood Clots in Patients With Lung Cancer
• Vinflunine and Cetuximab as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
• A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)
• Study With IMC-A12 in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
• Study of Safety and Effects of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
• A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)
• Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
• Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
• Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma
• Obatoclax Mesylate and Topotecan in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
• Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
• Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
• Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
• Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
• Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma
• Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
• A Safety Study of XL019 in Adults With Myeloproliferative Disorders
• A Study of Oral PX-478 in Advanced Solid Tumors or Lymphoma
• Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
• STA-4783 With Paclitaxel Versus Paclitaxel Alone in Melanoma
• Clinical Trial to Test the Safety and Effectiveness of an Investigational Drug CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
• A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
• A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
• Phase I/II Study of SOL for Untreated Metastatic Colorectal Cancer
• Phase II Single Arm BIBW 2992 in NSCLC With EGFR Activating Mutations
• Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer
• p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Oesophageal Cancer
• Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
• Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain
• Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.
• Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
• Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer
• A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) Versus Pemetrexed in Advanced Non Small Cell Lung Cancer
• A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
• Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
• Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-Cis-Retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
• Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
• A Study To Find the Best Dose of SU011248 When Given With Pemetrexed, Pemetrexed and Cisplatin Or Pemetrexed and Carboplatin in Patients With Advanced Solid Tumors
• AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
• Safety, Pharmacokinetics of Oral Azacitidine in Subjects With MDS and AML
• Azacitidine and Valproic Acid Plus Carboplatin in Patients With Platinum Resistant Epithelial Ovarian Cancer
• Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
• RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
• A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Second-Line Treatment of Patients With DLBCL
• A Phase II Study to Determine the Activity of Dasatinib in Chinese Subjects With Imatinib Resistant/Intolerant Chronic Phase, Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
• Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-Small Cell Cell Lung Cancer
• Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer.
• A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer
• Study of Salirasib to Treat Non-Small Cell Lung Cancer
• A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
• A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer
• A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
• Sorafenib in Resected Non-Small Cell Lung Carcinoma
• Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers
• A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.
• A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia
• A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
• An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-Sensitive Relapsed Ovarian Cancer
• Goserelin Plus Letrozole in Premenopausal Patients Versus Letrozole Alone in Postmenopausal Patients With Metastatic Breast Cancer
• Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
• Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
• Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
• An Open-Label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib (Glivec®/Gleevec®) - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
• Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma
• Phase II Study of Ironotecan Plus Capecitabine in Patients With Antracycline and Taxane Pretreated Metastatic Breast Cancer
• Hydralazine Valproate for Cervical Cancer
• Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab
• Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
• A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas
• ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma
• Hydralazine Valproate for Ovarian Cancer
• A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Myelodysplastic Syndrome (MDS)
• Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Patients With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy
• A Phase I/II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer
• BAY 43-9006 in Previously Untreated Patients With IIIB/IV NSCLC
• Safety Study of IMC-1121B With or Without Dacarbazine to Treat Metastatic Malignant Melanoma
• A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
• ABT-888, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
• Bevacizumab, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Previously Treated With Radiation Therapy and Temozolomide
• AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
• SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
• Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154
• Lenalidomide as Initial Treatment of Patients With CLL Age 65 and Older
• Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
• A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safety/Tolerability/Efficacy of Oral Gefitinib 250 mg Versus IV Docetaxel 60 mg/m2 in Patients With Locally Advanced or Metastatic NSCLCancer of Adenocarcinoma Histology Previous Treated With One Platinum Base Chemotherapy
• Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
• Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With CLL
• Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
• Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
• Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
• Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
• Study for Patients With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo
• Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
• Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients
• A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
• A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
• Phase II Study of 7 Days On/7 Days Off Temozolomide in Patients With High-Grade Glioma
• A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467)
• Safety and Tolerability Study of SNS-595 and Cytarabine Combination in Acute Myeloid Leukemia in Humans
• Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma
• Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bios HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
• Phase II Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases
• Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
• A Trial of PROSCAR (Finasteride) vs. Placebo in Men With an Initial Negative Prostate Biopsy
• Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
• Study of NK012 in Patients With Refractory Solid Tumors
• Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
• Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
• Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor
• Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
• Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer (NSCLC)
• Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
• Continuous Oral Abiraterone in Castration Resistant Prostate Cancer
• Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
• Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme
• BEVACIZUMAB + LETROZOL vs LETROZOL as First Line Treatment in Postmenopausal Patients With Advanced or Metastatic Breast Cancer
• A Study Of RN624 (PF-04383119) And Oxycodone In Patients With Pain Due To Cancer That Has Spread To Bone
• A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients
• Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
• Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer
• Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
• Phase II Dasatinib Study in Advanced Breast Cancer
• Feasibility Study of CDDP + CPT-11 + PSK for ED Small Cell Lung Cancer
• Preoperative Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
• A Phase 1/2 Study of BMS-753493 in Subjects With Advanced Cancer
• This is a Study of Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer
• Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
• A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
• Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
• A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-Line Therapy in Patients With Advanced Gastric Cancer (AVAGAST)
• Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer
• Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
• A Phase 1/2 Study of BMS-753493 in Subjects With Advanced Cancer (Schedule 2)
• Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine
• Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-Positive Breast Cancer (Study P05048)
• A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL
• A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed or Recurrent Colorectal Cancer (Study P04721)
• A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
• A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.
• Pertuzumab, Cetuximab, and Irinotecan in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
• Gemtuzumab and Combination Chemothearpy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
• Phase I Clinical and PK Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors
• Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer-Prospective, Randomized Phase II Clinical Trial
• Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
• Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
• A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
• Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients
• Immunogenicity and Safety of GlaxoSmithKline Biologicals HPV Vaccine 580299 in Healthy Females 15 - 25 Years of Age
• Phase II Study of Bevacizumab and Erlotinib
• Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer
• Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-Cell Lymphoma With Neuromeningeal Invasion at Diagnosis
• Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.
• G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
• CT-322 With or Without Irinotecan in Treating Patients With Recurrent Glioblastoma Multiforme
• Whole-Brain Radiation Therapy and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer and Brain Metastases
• Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
• Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma
• Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
• Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
• Lapatinib in Treating Women With Ductal Carcinoma In Situ of the Breast
• A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
• Lamivudine as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
• Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)
• Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas
• Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure
• A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy
• Study of Sunitinib in Combination With Cisplatin/Capecitabine or Oxaliplatin/Capecitabine in Patients With Advanced Gastric Cancer
• A Phase I Study of Sunitinib in Combination With Cisplatin and 5-Fluorouracil in Patients With Advanced Gastric Cancer
• Safety and Efficacy of ALC in Breast Cancer Subjects With Fatigue
• An Invstigational Drug, PD 0332991, is Being Studied in Combination With Velcade and Dexamethasone in Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment for Multiple Myeloma.
• ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer
• A Phase 1 Study Testing CP-675,206 + Gemcitabine in Patients With Metastatic Pancreatic Cancer
• Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-Risk Patients With Metastatic Renal Cell Carcinoma
• A Study of PF-03732010 in Patients With Advanced Solid Tumors
• Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
• Safety Study of Oxaliplatin and 5-Flurouracil Followed by FUDR for Unresectable Colorectal Liver Metastases
• A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer
• XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
• A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
• A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma
• Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
• A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer
• A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
• A Phase I Study to Assess the Safety and Distribution of GT-111 in Patients With Advanced Metastatic Cancer
• A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia
• A Study of MK8033 in Patients With Advanced Solid Tumors
• DNA Analysis in Predicting Lung Cancer Risk
• Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
• Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
• AZD0530 in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
• A Study of R7112 in Patients With Advanced Solid Tumors.
• A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.
• Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer
• Enzastaurin and Bevacizumab in Treating Patients With Recurrent Malignant Gliomas
• Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine
• Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC
• An Open-Label, Single-Center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
• Diffuse Large B Cell Lymphoma of the Adult: Randomisation Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab
• Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
• Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in theTreatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
• Sunitinib in Treating Patients With Recurrent or Unresectable Meningioma, Intracranial Hemangiopericytoma, or Intracranial Hemangioblastoma
• A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients
• Feasibility Study of Pazopanib in Combination With Chemo in Gyn Tumors
• Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
• Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
• Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
• Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
• CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
• Sorafenib/Docetaxel Dose Escalation Trial
• Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years
• Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
• Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin,in Pancreatic Cancer
• Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer
• A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-Resistant Prostate Cancer
• Combination of GTI 2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)
• Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
• Phase I/II XP+Sorafenib in AGC
• Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer
• Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
• Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
• New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer
• A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours
• Phase I/II Study of Dasatinib in Combination With Zoledronic Acid
• Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome
• Phase I- Lapatinib and Epirubicin Study
• A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (CLEOPATRA)
• A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)
• A Trial of LBH589 and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed on or After Trastuzumab
• 1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
• A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer (DLT)
• Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
• Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
• Phase III Study of PI-88 in Post-Resection Hepatocellular Carcinoma (PATHWAY)
• Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
• Identification of Serum Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancer
• Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer
• Phase II Study of ASP3550 in Patients With Prostate Cancer
• Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer
• Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
• Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
• Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
• Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
• Study of Weekly DCF to Treat Advanced Gastric Cancer
• Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Patients With Advanced or Metastatic Solid Tumors
• Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory AML or High Risk MDS
• Molecular Analysis of Breast Cancer
• Phase 1 Study of TG01 and Erlotinib in Non-Small Cell Lung Cancer (NCSLC) Patients
• A Study of the Safety, Tolerability of TAK-700 in Subjects With Metastatic, Androgen-Independent Prostate Cancer
• Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
• Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors (-)
• Vaccine Therapy in Treating Patients Who Have Undergone Autologous Stem Cell Transplant for High-Risk Lymphoma or Multiple Myeloma
• Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer
• Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Undergoing Treatment for Newly Diagnosed Breast Cancer
• Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
• Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)
• Treatment Protocol for Patients Continuing From SU011248 Protocols
• Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer
• Study of AG-013736 (Axitinib) as Second-Line Treatment in Patients With Metastatic Renal Cell Cancer (mRCC)
• Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma
• Combination Bortezomib-Containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma
• UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer (UAB 0718)
• A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors
• Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
• Arimidex With Or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer (PACT 001)
• The Role of Eriotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome
• Dasatinib in Treating Patients With Advanced Non-Small Cell Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
• Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
• Randomized Phase II Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced RCC
• Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-Dose Chemotherapy (EmNa)
• A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
• Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors
• MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
• UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (2006-66)
• Clofarabine, Melphalan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Diseases
• Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
• Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin
• Safety and Efficacy Study of FLT Radiolabeled Imaging Agent With PET Scan in Invasive Breast Cancer
• A Combination of Imatinib Mesylate & Pegylated Interferon-α2a in Chronic-Phase Chronic Myeloid Leukemia (UMCC 2006-128)
• Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
• Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada
• Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors
• ABI-009 (Nab-Rapamycin) in Patients With Advanced Non-Hematologic Malignancies
• Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
• UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide (2006-15)
• Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
• Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
• Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients
• Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer
• Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis
• A Study to Test the Safety & Effectiveness of Docetaxel With RAD001 & Bevacizumab in Men With Advanced Prostate Cancer
• EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer
• Obatoclax Mesylate, Fludarabine and Rituximab in Previously Treated Patients With B-CLL
• AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
• Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme (Temodar)
• Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer
• MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients With Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial
• Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer
• SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
• Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
• Gemcitabine and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
• SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial (SPRUCE)
• Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects
• Molecular Reasons for Acquired Clinical Resistance to Erlotinib and Gefitinib in Non-Small-Cell Lung Cancer
• Study of Breast Cancer Prevention by Letrozole in High Risk Women
• A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia
• Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors
• Preoperative Cisplatin and Bevacizumab in ER-, PR-, Her-2 Negative Breast Cancer
• Study of S-1 Versus Capecitabine as First-Line Chemotherapy in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer
• Molecular Urine Tests for Prostate Cancer
• Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
• Erlotinib and Sunitinib in NSCLC
• Ph 2 Bortezomib + Doxorubicin for Previously Treated Multiple Myeloma
• Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer (RAD0201)
• A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
• Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Releated or Unrelated Donor
• Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers
• Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML
• Phase I & II Trial of Intravesicular Abraxane for Treatment-Refractory Bladder Cancer (Abraxane)
• A Randomized, Controlled Trial of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination With IMRT Versus IMRT Alone for the Treatment of Newly-Diagnosed Intermediate-Risk Prostate Cancer
• Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
• Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
• Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21 (APP21)
• A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer (NSCLC)
• A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer
• A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
• A Study to Assess the Safety of Administering CP-675,206 as a One Hour Infusion in Patients With Surgically Incurable Advanced Melanoma
• A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
• A Study of Oral PF-02341066, a c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, in Patients With Advanced Cancer
• Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
• A Blinded, Randomized, Phase I Study of Brivanib Alaninate vs Placebo in Combination With Erbitux (Cetuximab) and Irinotecan in Subjects With Metastatic Colorectal Cancer (MCRC)
• Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
• Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies
• Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Newly-Diagnosed Primary CNS Lymphoma (PCNSL)
• A Study of XL184 With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
• A Phase I/II Study of Dasatinib and Dacarbazine
• Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
• Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer
• Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
• Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva. (ACT)
• Phase II Trial Of ZK-EPO (ZK 219477) In Metastatic Melanoma
• Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic HSCT (AlloTreo)
• A Phase 2a/2b Multicenter, Open-Label Study to Evaluate NKTR 102 (PEG-Irinotecan) in Combination With Cetuximab Versus Irinotecan in Combination With Cetuximab in Second Line Colorectal Cancer Patients
• Angiogenesis in Early Breast Cancer for Prognosis Prediction
• Phase I Study of Sunitinib Plus FOLFOX in Patients With Solid Tumors
• Etoposide and Cisplatin in Treating Young Patients With Previously Untreated High-Risk Neuroblastoma Undergoing High-Dose Chemotherapy, Stem Cell Transplant, and Isotretinoin
• Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer
• A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
• 2-Arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
• A Phase I, Open-Label, Multi-Center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
• A Study of IV Casopitant for the Prevention of Chemotherapy Induced Nausea and Vomiting
• A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
• Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.
• Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer
• Study of Non-Small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-Based Treatment
• Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors
• Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
• Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer
• Radiation Therapy and Cisplatin With or Without Fluorouracil in Treating Patients With Stage III or Stage IV Head and Neck Cancer
• Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
• A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblasto
• A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer
• An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) to Treat Relapsed or Refractory Multiple Myeloma or Non-Hodgkins Lymphoma
• Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer
• Study of Oral Palifosfamide Tris in Solid Tumors
• Phase 1 Study of MPC-6827 and Temozolomide in Melanoma Metastatic to the Brain
• Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
• Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
• Vandetanib in Treating Patients With Unresectable or Metastatic Kidney Cancer
• Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
• Phase II Study in Patients With Advanced Ovarian Cancer (OVERT-1)
• Pharmacokinetics Study of Liposomal Paclitaxel in Humans (LPS-PK-H)
• Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Primary Refractory Lymphoma
• Safety and Efficacy Study of GCS-100 in the Treatment of Multiple Myeloma
• Naproxen in Preventing Bone Pain Caused by Pegfilgrastim in Patients With Non-Hematologic Cancer Undergoing Chemotherapy
• Gene-Modified Tumor Cells in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
• Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
• A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
• An Exploratory, Open Label, Single Center Study of [F-18]HX4
• GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
• Lapatinib and/or Trastuzumab With or Without Paclitaxel in Treating Patients With HER2-Positive Breast Cancer Who Have Undergone Surgery
• Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
• Sorafenib/Carboplatin/Paclitaxel in Patients With Solid Tumors
• Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening (SPIT-LC)
• Ph II Avastin + Bortezomib for Pts w Recurrent Malignant Glioma
• Study to Evaluate Erlotinib With or Without SNDX-275 in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
• Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
• Ph II Imatinib Mesylate + Hydroxyurea in Treatment for Pts w Recurrent/Progressive Meningioma
• Treatment Outcomes of Hepatic Metastasis After FOLFOX-4 Therapy
• A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer
• CerviPrep™ for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial Cancer, Cervical Cancer, or Ovarian Epithelial Cancer
• High-Dose Cytarabine and Mitoxantrone in Treating Patients With Juvenile Myelomonocytic Leukemia Undergoing a Second Donor Stem Cell Transplant
• A Study of Ispinesib in Metastatic Breast Cancer
• IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor
• F-18 16 Alpha-Fluoroestradiol Imaging in Predicting Response to First-Line Hormone Therapy in Women With Hormone Receptor-Positive Metastatic Breast Cancer
• A Study of Radiation With Sorafenib in Advanced Cancer
• Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
• Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment
• Phase II Temozolomide in Acute Myeloid Leukemia Patient Age >= 60 Yrs & Poor Risk/Refractory Disease
• Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fudarabine-Based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
• Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
• Anti-CD45 Monoclonal Antibody, Alemtuzumab, and Fludarabine Followed By Donor Stem Cell Transplant in Treating Children With Severe Combined Immunodeficiency Disease or Other Primary Immunodeficiency Disorder
• Dasatinib in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
• Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059 AM2)
• SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
• Ph I Trial of Oral Topotecan + Temo in Treatment of Pts w Malignant Gliomas
• Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
• MP470 and Chemotherapy in Treating Patients With Cancer
• Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
• Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
• Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
• Temozolomide in Treating Patients With Invasive Pituitary Tumors
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer
• Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens
• AZD0530 as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
• Study of SNS-595 in Older Patients With Untreated Acute Myeloid Leukemia
• Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
• Ph I Dasatinib + Erlotinib in Recurrent MG
• Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
• Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients (Z-MARK)
• Gemcitabine and Erlotinib With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
• huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
• Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer
• Temozolomide in Treating Patients With Recurrent High-Grade Glioma
• PR-104 and G-CSF in Treating Patients With Solid Tumors
• Letrozole and Erlotinib in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Locally Recurrent or Metastatic Breast Cancer
• FDG-PET Pharmacodynamic Assessment of BIIB021 in GIST
• Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
• A Phase 1 Study of 1-Methyl-D-Tryptophan in Patients With Advanced Malignancies
• A Study of LY2181308 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
• Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer
• A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
• Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours
• Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
• Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
• Phase II Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC) (GAO2)
• Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
• A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
• Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
• Phase II Breast Cancer Treatment Using Weekly Carboplatin+Nab-Paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-)
• Phase I Safety and Tolerability Study of AZD2171 in Combination With Chemo in First Line Lung Cancer Patients
• Lapatinib, Cisplatin, Gemcitabine With or Without Paclitaxel as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer
• Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor
• Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
• Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Vorinostat in Treating Women With Breast Cancer That Can Be Removed by Surgery
• Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma (TORAVA)
• Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
• Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
• Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
• Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
• Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed MM
• A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
• Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
• Phase II Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer (GAO1)
• Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
• Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma
• A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
• High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Germ Cell Tumors
• A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer.
• Amgen Protocol No. 20060362-Breast Cancer Phase 2 Clinical Trial
• Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
• Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
• Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
• Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
• Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
• Chemotherapy, Radiation Therapy, and Vaccine Therapy With or Without Daclizumab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
• Anastrozole or Fulvestrant in Treating Postmenopausal Women With Stage II or Stage III Breast Cancer That Can Be Removed By Surgery
• A Study Evaluating the Safety and Antitumor Activity of IP-504, in Patients With Metastatic Melanoma
• RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
• Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
• A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer
• Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
• Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
• A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer (FP253-GDEPT)
• A Study of Leuprolide 45 mg Formulation to Treat Prostate Cancer.
• Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
• A Pharmacokinetic and Phase II Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors
• Combination Chemotherapy Followed By Docetaxel or Ixabepilone in Treating Patients Who Have Undergone Surgery for Nonmetastatic Breast Cancer
• Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
• Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men Receiving Glucocorticoids for Newly Diagnosed High-Grade Glioma
• Multi-Center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
• Alemtuzumab, Fludarabine, Melphalan, and a Donor Stem Cell Transplant in Treating Young Patients With Resistant Langerhans Cell Histiocytosis
• PET Imaging of High-Grade Glioma Using 18F-Fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?
• Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease
• RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
• Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
• Pazopanib in Treating Patients With Advanced Thyroid Cancer
• Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis
• Phase 2 Study of ALIMTA in Patients With Recurrent or Metastatic NPC Who Have Had Prior Platinum Based Chemotherapy
• Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma
• Dose-Finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer (ICEBERG 3)
• A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
• Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
• A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer (BNIT-PR-001)
• Oral NRX 194204 in Patients With Refractory Malignancies
• Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
• Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer (CILAB)
• Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer
• A Study of R7112 in Patients With Hematologic Neoplasms.
• Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
• Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01) (ABX067)
• Phase 1 Clinical Trial in Patients With Advanced Malignancies
• Sorafenib Long Term Extension Program (STEP)
• Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant
• Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma
• Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma
• Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors
• Vaccine Therapy and Chemotherapy With or Without Tretinoin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
• Hyperthermic Intraperitoneal Oxaliplatin Followed by Intraperitoneal Leucovorin and Fluorouracil in Treating Patients With Peritoneal Cancer
• Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
• Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH)
• The Safety and Efficacy of CPTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors
• Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
• Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer (With Trastuzumab in HER2 Positive Patients)
• A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer.
• Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
• FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer (TOSCA)
• A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy in Cancer Patients
• Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer
• Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients
• Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
• Randomized Multicentric Phase II Study of Prolonged Adjuvant Temozolomide or "Stop and Go" in Glioblastoma Patients: The PATSGO Study
• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
• Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes
• Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery
• Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
• A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
• UMCC 2006.119 Phase I/II Trial of MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast Cancer: A Study by the Stem Cell Clinical Consortium
• AZD0530 in Treating Patients With Recurrent, Stage IIIB or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy That Included Cisplatin or Carboplatin
• KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
• Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL
• A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype
• A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.
• Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-Small Cell Lung Cancer (TP2001-201)
• TaCyDexVMP7: Alternating (VAMP)/(TaCyDex) in Patients < 75 Years or (V-MP)/TaCyDex)in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma
• Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
• A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors
• Efficacy Study of CYT997 in Combination With Carboplatin and Etoposide in Glioblastoma
• Vorinostat + Revlimid + Dexamethasone in Multiple Myeloma
• A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies
• Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
• Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
• AZD2281 and Carboplatin in Treating Patients With BRCA1/BRCA2-Associated or Hereditary Metastatic or Unresectable Breast and/or Ovarian Cancer
• Safety Study of SNX-5422 to Treat Solid Tumor Cancers and Lymphomas
• A Safety and Dose-Finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors
• A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Patients With Advanced Malignancies
• Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer
• A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
• Cetuximab With or Without Brivanib in Treating Patients With Metastatic Colorectal Cancer
• SNX-5422 Mesylate in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment
• A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ARRY-380 Given on a Daily Oral Regimen in Subjects With Advanced Cancer
• MATER Study: A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash
• Dasatinib in Resectable Malignant Pleural Mesothelioma
• Letrozole in Treating Postmenopausal Women With Stage I or Stage II Breast Cancer That Can Be Removed by Surgery
• Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
• Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
• Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer
• Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients
• An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)
• Atorvastatin in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer
• Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer
• Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1
• A Phase I Dose Escalation Study of Weekly SGN-35 Alone and in Combination With Gemcitabine in HL
• A Dose-Finding and Double Blinded Study of JNS020 QD(Fentanyl) in Patients With Cancerous Pain Previously Untreated With Opioid Analgesics
• A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer
• Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas
• Positron Emission Tomography-Computed Tomography (PET-CT) High-Grade Glioma
• Randomized Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
• Phase 1 Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
• Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome (MDS) Who Are Candidates For Allogeneic Hematopoietic Cell Transplant
• Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
• A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
• Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-Cisplatin for Extensive Disease Small Cell Lung Cancer
• Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
• A Phase II Study of AZD4877 (a Novel Anti-Mitotic Agent) in Advanced Bladder Cancer
• Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
• Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
• Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors
• Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM), Who Have Failed Previous Mobilization
• Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients With High-Risk MDS and AML
• Pemetrexed Disodium With or Without Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Responded to Previous Erlotinib
• A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer
• Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
• A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma (KARE004)
• Vaccine Therapy and Cyclophosphamide in Treating Patients Who Has Undergone Surgery for Liver Metastases Due to Colorectal Cancer
• Phase 2 Study Of Sunitinib With Capecitabine In Breast Cancer
• Phase I Study of GemOx and Vandetanib in Advanced Solid Malignancy
• A Phase II Uncontrolled Study of BAY 73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
• Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage I, Stage II, Stage III, or Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma
• A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
• Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
• CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy
• Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
• Efficacy and Safety of Zactima™ in Patients With Castration-Refractory Metastatic Prostate Cancer
• Sorafenib Gastric Cancer Asian Phase I Study
• Magnetic Resonance (MR) Imaging Study Using Ferumoxytol to Assess Early Tumor Response in Patients With Glioblastoma Multiforme
• Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib
• ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
• Study of AV-951 Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
• Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers
• AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
• Phase 1 Study of MKC-1 in Patients With Advanced Cancer
• Phase II Study of ABI-007 for Gastric Cancer
• A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
• A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer